Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib Mesylate in Nephrogenic Systemic Fibrosis
NCT00981942Phase 3Completed
- Sponsor
- Aarhus University
- Start
- Sep 2009
- Primary completion
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of imatinib in nephrogenic systemic fibrosis (NSF), sponsored by Aarhus University. Primary endpoints: Skin fibrosis at 28 weeks and Joint mobility at 28 weeks. Started Sep 2009; status: completed.
02
Drugs
03
Conditions
nephrogenic systemic fibrosis (NSF)
Beyond the preview
Go deeper on NCT00981942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00981942.